Literature DB >> 12111813

Attenuated plasticity in neurons and astrocytes in the mouse model of Sanfilippo syndrome type B.

Hong Hua Li1, Hui-Zhi Zhao, Elizabeth F Neufeld, Yan Cai, Fernando Gómez-Pinilla.   

Abstract

Sanfilippo syndrome type B (MPS III B) is a neurodegenerative disorder characterized by profound mental retardation and early death. It is caused by deficiency of a lysosomal enzyme involved in heparan sulfate (HS) degradation. Because HS accumulation can be a major feature of this disease, we have examined crucial molecular systems associated with HS function. Using a knockout mouse with disruption of the gene responsible for HS degradation, we evaluated the effects of possible HS accumulation on neuroplasticity that are within the spectrum of action of fibroblast growth factors (FGFs) and their receptor (FGFR). We found that levels of mRNA for the FGFR-1 were attenuated in the mutant mice by the age of 6 months, whereas the mRNAs for FGF-1 and FGF-2 were reduced or unchanged in the brain regions tested. Neurogenesis, in which FGF-2 is involved, was inhibited in the MPS III B mouse brain at both young and adult ages. We also examined the expression of the glial fibrillary acidic protein (GFAP) gene and GFAP-positive cell density in both normal and injured conditions to study the functional response of astrocytes to insult. We found that, although the mutation alone caused drastic induction of reactive astrocytes, acute injury to the mutant brains failed to induce additional reactive astrocytes. Our results showed important alterations in the expression of several genes involved in the maintenance of neuroplasticity in the MPS III B. This in turn may result in reduction of neuronal health and brain function. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12111813     DOI: 10.1002/jnr.10278

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  35 in total

Review 1.  Pathophysiology of neuropathic lysosomal storage disorders.

Authors:  Cinzia Maria Bellettato; Maurizio Scarpa
Journal:  J Inherit Metab Dis       Date:  2010-04-29       Impact factor: 4.982

2.  Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB.

Authors:  Coy D Heldermon; Kevin K Ohlemiller; Erik D Herzog; Carole Vogler; Elizabeth Qin; David F Wozniak; Yun Tan; John L Orrock; Mark S Sands
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

3.  Near-Complete Correction of Profound Metabolomic Impairments Corresponding to Functional Benefit in MPS IIIB Mice after IV rAAV9-hNAGLU Gene Delivery.

Authors:  Haiyan Fu; Aaron S Meadows; Tierra Ware; Robert P Mohney; Douglas M McCarty
Journal:  Mol Ther       Date:  2017-01-28       Impact factor: 11.454

4.  Evaluation of Disease Lesions in the Developing Canine MPS IIIA Brain.

Authors:  Leanne K Winner; Neil R Marshall; Robert D Jolly; Paul J Trim; Stephen K Duplock; Marten F Snel; Kim M Hemsley
Journal:  JIMD Rep       Date:  2018-06-20

5.  A GLP-Compliant Toxicology and Biodistribution Study: Systemic Delivery of an rAAV9 Vector for the Treatment of Mucopolysaccharidosis IIIB.

Authors:  Aaron S Meadows; F Jason Duncan; Marybeth Camboni; Kathryn Waligura; Chrystal Montgomery; Kimberly Zaraspe; Bartholomew J Naughton; William G Bremer; Christopher Shilling; Christopher M Walker; Brad Bolon; Kevin M Flanigan; Kim L McBride; Douglas M McCarty; Haiyan Fu
Journal:  Hum Gene Ther Clin Dev       Date:  2015-12       Impact factor: 5.032

6.  Abnormal polyamine metabolism is unique to the neuropathic forms of MPS: potential for biomarker development and insight into pathogenesis.

Authors:  Christian Hinderer; Nathan Katz; Jean-Pierre Louboutin; Peter Bell; Jakub Tolar; Paul J Orchard; Troy C Lund; Mohamad Nayal; Liwei Weng; Clementina Mesaros; Carolina F M de Souza; Amauri Dalla Corte; Roberto Giugliani; James M Wilson
Journal:  Hum Mol Genet       Date:  2017-10-01       Impact factor: 6.150

7.  Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery.

Authors:  Haiyan Fu; Julianne Dirosario; Smruti Killedar; Kimberly Zaraspe; Douglas M McCarty
Journal:  Mol Ther       Date:  2011-03-08       Impact factor: 11.454

8.  Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB.

Authors:  Kazuhiro Ohmi; David S Greenberg; Kavitha S Rajavel; Sergey Ryazantsev; Hong Hua Li; Elizabeth F Neufeld
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-07       Impact factor: 11.205

9.  Mucopolysaccharidosis IIIB, a lysosomal storage disease, triggers a pathogenic CNS autoimmune response.

Authors:  Smruti Killedar; Julianne Dirosario; Erin Divers; Phillip G Popovich; Douglas M McCarty; Haiyan Fu
Journal:  J Neuroinflammation       Date:  2010-07-16       Impact factor: 8.322

10.  Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates.

Authors:  Darren A Murrey; Bartholomew J Naughton; F Jason Duncan; Aaron S Meadows; Tierra A Ware; Katie J Campbell; William G Bremer; Christopher M Walker; Laurie Goodchild; Brad Bolon; Krista La Perle; Kevin M Flanigan; Kim L McBride; Douglas M McCarty; Haiyan Fu
Journal:  Hum Gene Ther Clin Dev       Date:  2014-04-10       Impact factor: 5.032

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.